You are here

plozasiran

Arrowhead’s RNAi therapeutic plozasiran shows promise in familial chylomicronaemia syndrome

PM Live

Tue, 09/3/24 - 11:23 am

Arrowhead Pharmaceuticals

familial chylomicronemia syndrome

Arrowhead axes heart disease drug, goes all in on another as pipeline progress drives costs up

Fierce Biotech

Wed, 06/26/24 - 10:05 am

Arrowhead Pharmaceuticals

cardiovascular disease

Arrowhead's much-anticipated cholesterol drug hits the mark again in phase 2 hyperlipidemia trial

Fierce Biotech

Thu, 05/30/24 - 11:04 am

Arrowhead Pharmaceuticals

clinical trials

Arrowhead's plozasiran could reach $700M-plus in sales by 2032, meet major unmet need in dyslipidemia: GlobalData

Fierce Pharma

Tue, 04/16/24 - 10:05 pm

Arrowhead Pharmaceuticals

clinical trials